Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ESPR | PRESS-RELEASE | neutral | 1/10 | Esperion Therapeutics, Inc. announced it will report its Q1 2026 results on May 7. | Apr 23, 2026 |
| COLL | PRESS-RELEASE | neutral | 1/10 | Collegium Pharmaceutical, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 23, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings Inc. (ELAB) announced that its subsidiary NorthStrive Defense Tech secured an exclusive option to license | Apr 23, 2026 |
| KYMR | PRESS-RELEASE | neutral | 1/10 | Kymera Therapeutics, Inc. announced it will report its Q1 2026 results on April 30, 2026. | Apr 23, 2026 |
| PBM | PRESS-RELEASE | bullish | 7/10 | Psyence Biomedical Ltd. (PBM) announced the first patient dosed in its Phase IIb clinical trial evaluating NPX-5, a natu | Apr 23, 2026 |
| ALT | PRESS-RELEASE | bearish | 7/10 | Altimmune announced the pricing of a public offering of common stock and pre-funded warrants, along with accompanying wa | Apr 22, 2026 |
| GLSI | PRESS-RELEASE | bearish | 7/10 | Greenwich LifeSciences announced a Nasdaq non-compliance notice due to its late filing of the 2025 Form 10-K, with no im | Apr 22, 2026 |
| SUPN | PRESS-RELEASE | neutral | 1/10 | Supernus Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 5, 2026. | Apr 22, 2026 |
| SILO | PRESS-RELEASE | mixed | 6/10 | Silo Pharma announced the launch of a new AI subsidiary following its acquisition of Qwikagents.ai assets, marking a str | Apr 22, 2026 |
| LFVN | PRESS-RELEASE | neutral | 1/10 | LifeVantage Corporation announced it will report its fiscal Q3 2026 results on May 6, 2026. | Apr 22, 2026 |
| LBRX | PRESS-RELEASE | bullish | 7/10 | LB Pharmaceuticals announced the publication of positive Phase 2 NOVA-1 trial data for LB-102 in schizophrenia in JAMA P | Apr 22, 2026 |
| TKNO | PRESS-RELEASE | neutral | 1/10 | Alpha Teknova, Inc. announced it will report its Q1 2026 results on May 6, 2026. | Apr 22, 2026 |
| QNTM | PRESS-RELEASE | neutral | 4/10 | Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., its majority-owned con | Apr 22, 2026 |
| WVE | PRESS-RELEASE | neutral | 1/10 | Wave Life Sciences USA, Inc. announced it will report its Q1 2026 results on April 28, 2026. | Apr 22, 2026 |
| MDGL | PRESS-RELEASE | neutral | 1/10 | Madrigal Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 6, 2026. | Apr 22, 2026 |
| OPK | PRESS-RELEASE | bullish | 7/10 | OPKO Health announced the initiation of patient dosing in a Phase 1 trial for MDX2003, a novel tetraspecific T-cell enga | Apr 22, 2026 |
| ZVRA | PRESS-RELEASE | neutral | 1/10 | Zevra Therapeutics announced it will host a conference call on May 6, 2026 to discuss its Q1 2026 results. | Apr 22, 2026 |
| RGEN | PRESS-RELEASE | neutral | 1/10 | Repligen Corporation announced it will report its Q1 2026 results on May 5, 2026. | Apr 22, 2026 |
| CRVO | PRESS-RELEASE | mixed | 6/10 | CervoMed Inc. (CRVO) presented new MRI data from its RewinD-LB Phase 2b trial showing that neflamapimod increased right | Apr 22, 2026 |
| TGTX | PRESS-RELEASE | neutral | 4/10 | TG Therapeutics announced new real-world and dosing data for BRIUMVI® (ublituximab-xiiy) in relapsing multiple sclerosis | Apr 22, 2026 |
| ATHE | PRESS-RELEASE | bullish | 8/10 | Alterity Therapeutics announced new Phase 2 data for its drug ATH434 in Multiple System Atrophy (MSA), showing a statist | Apr 22, 2026 |
| GERN | PRESS-RELEASE | neutral | 1/10 | Geron Corporation announced it will report its Q1 2026 results on May 6, 2026. | Apr 22, 2026 |
| NRIX | PRESS-RELEASE | mixed | 6/10 | Nurix Therapeutics presented new preclinical data at AACR 2026 across its oncology pipeline, including pan-mutant BRAF d | Apr 22, 2026 |
| AMRX | PRESS-RELEASE | bullish | 9/10 | Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted di | Apr 22, 2026 |
| AAPG | PRESS-RELEASE | bullish | 7/10 | Ascentage Pharma announced that six clinical study abstracts for its key drug candidates, Olverembatinib, Lisaftoclax, a | Apr 21, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metastatic pancreatic can | Apr 21, 2026 |
| BBOT | PRESS-RELEASE | bullish | 7/10 | BBOT presented new preclinical data for BBO-10203, a first-in-class RAS:PI3Kα breaker, showing tumor regressions and str | Apr 21, 2026 |
| ZYME | PRESS-RELEASE | bullish | 8/10 | Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed o | Apr 21, 2026 |
| RVMD | PRESS-RELEASE | bullish | 7/10 | Revolution Medicines announced preclinical data for RM-055, a novel oral catalytic RAS(ON) inhibitor, showing deep and d | Apr 21, 2026 |
| AUTL | PRESS-RELEASE | neutral | 3/10 | Autolus Therapeutics granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees as inducement awards unde | Apr 21, 2026 |